RXRX(Recursion Pharmaceuticals, Inc.) · 财务报表

RXRX(Recursion Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$10.18M$39.84M$44.58M$58.84M$74.68M
毛利润$10.18M−$8.43M$1.99M$13.60M$3.73M
营业利润−$182.78M−$245.73M−$350.06M−$479.00M−$648.13M
净利润−$186.48M−$239.48M−$328.07M−$463.66M−$644.76M
经营现金流−$158.61M−$83.52M−$287.78M−$359.17M−$371.81M
自由现金流−$198.41M−$120.58M−$299.74M−$372.87M−$378.28M
摊薄每股收益$-1.49$-1.36$-1.58$-1.69$-1.44

Recursion Pharmaceuticals, Inc. RXRX